Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
Stocks in this Quantisnow insightHealth Care
Historical context for CRDL
Across the 22 sessions after earlier CRDL headlines, the stock closed higher 14 times and lower 7 times, with a median move of 2.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CRDL | SPY |
|---|---|---|---|
| Sep 11, 2026 | Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission | +0.8% | +0.9% |
| Sep 9, 2026 | Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference | +2.9% | -0.5% |
| Aug 26, 2026 | B. Riley Securities initiated coverage on Cardiol Therapeutics with a new price target | +7.0% | +0.0% |
| Aug 5, 2026 | Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference | -1.5% | -0.2% |
| Jul 14, 2026 | Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association | +8.5% | +0.4% |
| Jul 9, 2026 | Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit | -0.8% | +0.8% |
Quantisnow market dataNASDAQ
CRDL
Cardiol Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Get push alerts for CRDL
Full CRDL profile on Quantisnow Follow CRDL and get a push notification the moment its next story breaks.